Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03789708
Other study ID # 016227
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 1, 2018
Est. completion date June 1, 2019

Study information

Verified date December 2018
Source University of Khartoum
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Gum Arabic is a naturally produced gummy exudate from Acacia Senegal tree. It's a complex polysaccharide with proven prebiotic properties. Through its effect on intestinal bacteria, it's expected to reduce systemic levels of toxic bacterial metabolites and reduce inflammatory markers.By increasing fecal bacteria mass it's also expected to reduce blood urea level. These changes are potentially beneficial to hemodialysis patients who suffer from disturbed intestinal flora and a chronic inflammatory status. The investigators hypothesize that supplementing the diet of hemodialysis patients with Gum Arabic for four weeks would reduce inflammatory markers, increase total anti-oxidant capacity and reduce blood urea concentration.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date June 1, 2019
Est. primary completion date March 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult end-stage renal disease patients maintained on regular hemodialysis

Exclusion Criteria:

- Chronic liver disease

- Malignant condition

- Inflammatory bowel disease

- History of bowel resection

- Long term antibiotic therapy

- Pregnancy or lactation

- Current use of immunosuppressive medication

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Gum Arabic
Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
Other:
Placebo
Maltodextrin powder, easily soluble

Locations

Country Name City State
Sudan Doctor Salma Center for Kidney Diseases Khartoum

Sponsors (3)

Lead Sponsor Collaborator
University of Khartoum Almughtaribeen University, National Center for Kidney Diseases and Surgery

Country where clinical trial is conducted

Sudan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Highly sensitive C-reactive protein (hs CRP) level Change in serum level of highly sensitive C-reactive protein. 4 weeks
Primary Total anti-oxidant capacity Change in serum total anti-oxidant capacity 4 weeks
Primary Blood urea level Change in urea blood level 4 weeks
Secondary Serum calcium Change in serum calcium level 4 weeks
Secondary Serum phosphorus Change in serum phosphorus level 4 weeks
Secondary Serum uric acid Change in serum uric acid level 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT02922361 - Spending and Outcomes for Complex Medicare Advantage Patients
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Completed NCT01930396 - Use of Tinzaparin for Anticoagulation in Hemodialysis Phase 4
Completed NCT01922843 - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis Phase 2
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Not yet recruiting NCT01674660 - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients N/A
Not yet recruiting NCT01157260 - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Phase 4
Completed NCT01209403 - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Phase 4
Completed NCT00753116 - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension Phase 1
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Completed NCT00534144 - Comparison Between Effects of Two Iron Preparations on Protein in the Urine Phase 1
Completed NCT00528788 - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Phase 4
Completed NCT00382044 - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients N/A
Completed NCT00226902 - Vascular Reactivity in Kidney Disease Patients N/A
Recruiting NCT00235287 - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Phase 4
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00071214 - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis Phase 3
Completed NCT00049907 - Cardiac and Renal Disease Study (CARDS) N/A
Completed NCT00006297 - Risk Factors for CV Disease in a Dialysis Cohort N/A